Pyrotinib therapy in HER2+ breast cancer

Pyrotinib therapy in HER2+ breast cancer Breast cancer with human epidermal growth factor receptor 2 (HER2) occurs in almost 15-20% of all breast cancers. This type of cancer also shows aggressive clinical behavior and has a poor prognosis. The development and use of anti-HER2 drugs have improved outcomes for patients with

Breast Tomosynthesis Simulator for Virtual Clinical Trials

Breast Tomosynthesis Simulator for Virtual Clinical Trials Summary  The use of computer models and simulation in predicting the clinical performance of x-ray imaging devices in silico and generating synthetic patient images for training and testing of machine learning algorithms is widely accepted today.  In this study, the researchers presented a detailed description of

Pyrotinib therapy in HER2+ breast cancer